'Wave of future' cancer pill OK'd

Article Abstract:

Novartis Pharmaceutical has received FDA approval for its Gleevec product, indicated for the treatment of chronic myeloid leukemia, which afflicts 5,000 people each year in the US. Experts hailed the approval of Gleevec, the first of a new generation of anti-cancer drugs, which could also possibly be used against a form of stomach cancer, small-cell lung cancer, prostate cancer and brain tumors. The drug has milder side effects than chemotherapy, notably low white and red blood cell counts, fluid retention and nausea.

Pharmaceutical Preparation Manufacturing, Anticancer Drugs, Patents & copyrights, Antineoplastic agents, Novartis Pharmaceutical

---

DNA microchip detects cancer types

Article Abstract:

Researchers at Whitehead Institute for Biomedical Research in Cambridge, MA, used DNA microchips to detect two types of leukemia in a trial test. It marks the first time that DNA microchips are used as precision diagnostic tools. The microchips, which are primarilly pieces of etched glass layered with genes or pieces of genes, interact in specific ways with the DNA of whatever material is placed on them.

Semiconductor and Related Device Manufacturing, Microprocessor Chips, Science & research, CPUs (Central processing units)

---

Similar abstracts:

• Abstracts: Apple introduces what it calls an easier to use portable music player. Agreement is a first step for licensing online music
• Abstracts: Legend provides 4 feet of legroom, plus cheesecake. Want to save on your energy bills? Check the Net. Buyers still want homes of their own
• Abstracts: New hospitals preview the future. Justice alleges fraud at Tenet. Columbia agrees to $745M penalty
• Abstracts: Playing war, but with a new set of rules. In a shoot-em-up, three's company

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.